C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry. C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3(R)) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurodegeneration and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards the pre-clinical licensing discussions. In selecting new targets and executing new drug discovery programmes, C4X Discovery focuses on high-value disease areas that are the subject of significant licensing activity and will continue to also maximise value from opportunistic areas such as addiction and diabetes. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to $294m. The Company was founded as a spin-out from the University of Manchester. t has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO. Website: www.c4xdiscovery.com Twitter: @C4XDiscovery
View Top Employees from C4X Discovery LtdWebsite | http://www.c4xdiscovery.com/ |
Ticker | LSE:C4XD |
Revenue | $12 million |
Funding | $6.2 million |
Employees | 47 (47 on RocketReach) |
Founded | 2008 |
Phone | +44 161 606 7203 |
Technologies |
JavaScript,
HTML,
PHP
+22 more
(view full list)
|
Industry | Biotechnology, Pharmaceutical Manufacturing, Pharmaceuticals, Healthcare, Science and Engineering, Drug Manufacturing & Research, Life Science, Pharmaceutical, Health Care |
Web Rank | 5 Million |
Keywords | C4x Discovery, Etherapeutics, C4x Discovery Analyst Report, C4x, C4xd |
Competitors | 4Sc Ag, ActivX Biosciences, Domainex, International Therapeutics Inc, Provid Pharmaceuticals |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular C4X Discovery Ltd employee's phone or email?
The C4X Discovery Ltd annual revenue was $12 million in 2024.
Clive Dix is the CEO of C4X Discovery Ltd.
47 people are employed at C4X Discovery Ltd.
The NAICS codes for C4X Discovery Ltd are [32, 325, 3254, 32541].
The SIC codes for C4X Discovery Ltd are [28, 283].